Does slow-release 5-fluorouracil and triamcinolone reduce subglottic stenosis?

Area of Science:

• Otolaryngology
• Regenerative Medicine
• Pharmacology

Background:

• Subglottic stenosis, a narrowing of the airway below the vocal cords, often recurs after surgical intervention.
• Scar formation (fibroblast proliferation) is a primary cause of restenosis.
• Current treatments for subglottic stenosis have limitations in preventing recurrence.

Purpose of the Study:

• To investigate the efficacy of a slow-release combination of 5-fluorouracil (an antiproliferative agent) and triamcinolone acetonide (a corticosteroid) in preventing subglottic stenosis.
• To assess the safety and effectiveness of this compound in a rabbit model of induced subglottic stenosis.

Main Methods:

• Subglottic stenosis was surgically induced in rabbits.
• A suspension of 5-fluorouracil and triamcinolone acetonide was injected into the surrounding tissues at two concentrations (2.5 mg/ml and 12.5 mg/ml).
• A control group received the suspension vehicle without the active compounds. Stenosis was evaluated at 1, 2, and 12 weeks post-injection.

Main Results:

• No stenosis was observed at 1 or 2 weeks in any group.
• At 12 weeks, the rate of subglottic stenosis formation was significantly lower in the experimental groups (15.20%) compared to the control group (47.37%).
• No local or systemic toxicity was detected in the rabbits treated with the compound.

Conclusions:

• The combination of 5-fluorouracil and triamcinolone acetonide demonstrated a significant reduction in subglottic stenosis formation in a rabbit model.
• These preliminary findings suggest that this compound may be a promising therapeutic agent to reduce restenosis in patients undergoing surgical treatment for subglottic stenosis.
• Further research is warranted to validate these results and explore clinical applications.